Timing of Breast Cancer Surgery after Neoadjuvant Chemotherapy in COVID-19 Asymptomatic Patient: Case Report and Review of Literature

Cristina La Tessa, Valentina Galluzzo, Andrea Zarabini, Grazia Sorbo, Riccardo Ferrarini and Maria Cristina Cucchi

Division of Breast Surgery, Bellaria Hospital, Italy Department of Plastic Surgery, Bellaria Hospital, Italy

^*Correspondance to: Cristina La Tessa 

 PDF  Full Text DOI: 10.25107/2474-1647.2887

Abstract

COVID-19 pandemic overwhelmed our health care system. The need to preserve resources forced us to rethink therapeutic strategies and postpone all not priority surgeries. This situation is particularly critical for cancer patients. Different organizations developed recommendations set to guide the decision making of multidisciplinary team in breast cancer treatment strategy and most of them suggest postponing surgery procedures and shifting care to neoadjuvant chemotherapy and endocrinotherapy. However, this strategy has caused a backlog of breast cancer patients subjected to neoadjuvant chemotherapy and requiring surgery. A novel strategy is required to manage the percentage of these cases that are found COVID-19 infected. In this study, we report the clinical course and management of a young woman who completed cancer neoadjuvant chemotherapy, was then confirmed asymptomatic COVID-19 infection positive and underwent nipple-skin-sparing mastectomy with sentinel node biopsy and reconstruction with tissue expander.

Keywords

Cite the article

Tessa CL, Galluzzo V, Zarabini A, Sorbo G, Ferrarini R, Cucchi MC. Timing of Breast Cancer Surgery after Neoadjuvant Chemotherapy in COVID-19 Asymptomatic Patient: Case Report and Review of Literature. Clin Surg. 2020; 5: 2887.